Jincheng Medicine (300233.SZ) released its first quarter performance report, with a net profit attributable to the parent company of 35.05 million yuan, a decrease of 57.75%.

Zhijing Finance APP News: Jincheng Pharmaceutical (300233.SZ) released its first quarter report for 2025, with the company's operating income amounting to 722 million RMB, a decrease of 22.52% compared to the same period last year. Net profit attributable to shareholders of the listed company was 35.0548 million RMB, a decrease of 57.75% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 32.9526 million RMB, a decrease of 58.97% year-on-year. Basic earnings per share were 0.09 RMB.